Survival in small cell lung carcinoma is independent of bcl-2 expression

Anirban Maitra, Robin H. Amirkhan, M. Hossein Saboorian, William H. Frawley, Raheela Ashfaq

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.

Original languageEnglish (US)
Pages (from-to)712-717
Number of pages6
JournalHuman Pathology
Volume30
Issue number6
DOIs
StatePublished - Jun 1999

Fingerprint

Small Cell Carcinoma
Small Cell Lung Carcinoma
Survival
Oncogene Proteins
Neoplasms
Proportional Hazards Models
Citric Acid
Buffers
Carcinogenesis
Cell Death
Monoclonal Antibodies
Apoptosis
Antigens
Lung

Keywords

  • Bcl-2
  • Lung cancer
  • Small cell
  • Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Survival in small cell lung carcinoma is independent of bcl-2 expression. / Maitra, Anirban; Amirkhan, Robin H.; Saboorian, M. Hossein; Frawley, William H.; Ashfaq, Raheela.

In: Human Pathology, Vol. 30, No. 6, 06.1999, p. 712-717.

Research output: Contribution to journalArticle

Maitra, Anirban ; Amirkhan, Robin H. ; Saboorian, M. Hossein ; Frawley, William H. ; Ashfaq, Raheela. / Survival in small cell lung carcinoma is independent of bcl-2 expression. In: Human Pathology. 1999 ; Vol. 30, No. 6. pp. 712-717.
@article{9b8d347950164abaa3d2c573265e0c84,
title = "Survival in small cell lung carcinoma is independent of bcl-2 expression",
abstract = "Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10{\%} of noncrushed neoplastic cells. Twenty-five of 42 (60{\%}) patients had extensive disease at presentation, 10 of 42 (24{\%}) had limited disease, and 7 of 42 (16{\%}) had disease localized to the lung. Twenty-four of 42 (57{\%}) tumors were bcl-2 positive, and 18 of 42 (43{\%}) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.",
keywords = "Bcl-2, Lung cancer, Small cell, Survival",
author = "Anirban Maitra and Amirkhan, {Robin H.} and Saboorian, {M. Hossein} and Frawley, {William H.} and Raheela Ashfaq",
year = "1999",
month = "6",
doi = "10.1016/S0046-8177(99)90099-0",
language = "English (US)",
volume = "30",
pages = "712--717",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Survival in small cell lung carcinoma is independent of bcl-2 expression

AU - Maitra, Anirban

AU - Amirkhan, Robin H.

AU - Saboorian, M. Hossein

AU - Frawley, William H.

AU - Ashfaq, Raheela

PY - 1999/6

Y1 - 1999/6

N2 - Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.

AB - Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.

KW - Bcl-2

KW - Lung cancer

KW - Small cell

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0033025610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033025610&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(99)90099-0

DO - 10.1016/S0046-8177(99)90099-0

M3 - Article

C2 - 10374782

AN - SCOPUS:0033025610

VL - 30

SP - 712

EP - 717

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -